LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 24, 2026, 10:47 AM UTC

FDA Approves Eli Lilly's Onswik For Type 2 Diabetes

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes The US Food and Drug Administration has approved Eli Lilly's NYSE:LLY once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering p L impact | REGULATION | Sep 24, 2026, 11:26 AM UTC E.ON warns of growing risk of attacks on energy infrastructure ESSEN, Germany, Sept 24 (Reuters) — Companies must prepare for successful attacks on critical power infrastructure as both physical and cyber threats continue to increase, the CEO L impact | REGULATION | Sep 24, 2026, 11:05 AM UTC Satellos wins FDA IND clearance for forazapadin in FSHD Satellos won FDA clearance for its IND to test forazapadin in facioscapulohumeral muscular dystrophy. FSHD Canada Foundation committed up to USD 5 million in non-dilutive milestone L impact | REGULATION | Sep 24, 2026, 11:05 AM UTC Mesoblast Limited (MSB) Wins FDA OK For New Ryoncil Potency Assay Mesoblast received FDA approval to implement its T-cell Proliferation Inhibition BioAssay (TIBA) for release and stability monitoring of commercial Ryoncil batches, alongside exist L impact | REGULATION | Sep 24, 2026, 11:03 AM UTC Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced tha L impact | REGULATION | Sep 24, 2026, 11:03 AM UTC Mesoblast wins FDA approval for new potency assay for Ryoncil commercial lots Mesoblast received FDA clearance to use a new potency assay, TIBA, for commercial release of Ryoncil (remestemcel-L-rknd) lots. Test will support release and stability monitoring, L impact | REGULATION | Sep 24, 2026, 11:02 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.